| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H17F3N2O4S |
| Molecular Weight | 426.409 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(CC(O)=O)C2=CC=CN=C2N1CC3=CC=C(C=C3C(F)(F)F)S(C)(=O)=O
InChI
InChIKey=GFPPXZDRVCSVNR-UHFFFAOYSA-N
InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)
| Molecular Formula | C19H17F3N2O4S |
| Molecular Weight | 426.409 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 1.1 nM [Kd] |
Sample Use Guides
Fevipiprant (QAW039) is currently in development for the treatment of allergic diseases. [3H]-QAW039 displayed high affinity for the human CRTh2 receptor (1.14 +/- 0.44 nM) expressed in Chinese hamster ovary cells, the binding being reversible and competitive with the native agonist prostaglandin D2.
